by Mischler MarCom | Sep 3, 2024 | Equities Market Commentary, Recent Deals
Mischler Financial Group’s August End-of-Month Equities Market Recap highlights the following topics and thoughts on what is in store as we move forward into September.* August: 10% mark-down turns into a month ~2% gain across indices The Great Unwind of 2024 (so...
by Mischler MarCom | Aug 29, 2024 | Company News, Equities Market Commentary, Recent Deals
#2 H.R. McMaster: Russia | Ukraine Update: What is the Real Objective? #3 H.R. McMaster : The Middle East Theatre: Strait of Hormuz – Is an Energy Security Crisis in the Cards? #4 H.R. McMaster ; The US & China: Investable Yet?? Is There a Face Saving...
by Mischler MarCom | Aug 13, 2024 | Company News, Recent Deals
On Aug 12 2024, Mischler Financial Group’s Special Advisor, and former National Security Advisor to the President LTG H.R. McMaster (Ret) provided his views via the most recent in a series of Geopolitical/Global Macro “SITREPs” The topics General McMaster touched on...
by Mischler MarCom | Aug 1, 2024 | Company News, Equities Market Commentary, Recent Deals
The Mischler Capital Markets’ June end-of-month equities market commentary pointed to the nearly historic negative correlation between major market stock indices, as mid-cap stocks and utilities caught up to the upward moves in big cap techs. In that spirit,...
by Mischler MarCom | Jul 2, 2024 | Equities Market Commentary, Recent Deals
Mischler Equities Market Summary : June 2024 Month End The Best of Times for Tech Titans…. A Stock Pickers Market for Many Others.Traders & Stock Analysts Suffering from Dispersion Confusion The Good News CEOs, Analysts & Market Technicians are Aligned with...
by Mischler MarCom | Jun 3, 2024 | Company News, Equities Market Commentary, Recent Deals
April Showers > May Flowers> Then Meh, Then the Month-End Mark-Up….. What Really Happened…Earnings Beats; Margins Better; Utes Make Historic Moves; Outlooks Tempered (Again) Mixed Bags; What Keeps F500 CEOs and CFOs up at night now? Generative AI: Should the FDA...
